Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series

Arch Womens Ment Health. 2007;10(3):125-7. doi: 10.1007/s00737-007-0181-0. Epub 2007 Apr 16.

Abstract

The efficacy and tolerability of symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD) was evaluated in an open trial. Eight outpatients, aged 18-45 years and diagnosed with PMDD, were treated with 10-20 mg of citalopram from the start of premenstrual symptoms until the onset of menses. Primary efficacy variables were the premenstrual tension scale (PMTS-O) and the clinical global impression of improvement (CGI). Treatment was associated with significant improvement in PMDD symptoms (p < 0.001).

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antidepressive Agents, Second-Generation / administration & dosage*
  • Citalopram / administration & dosage*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Humans
  • Luteal Phase / drug effects
  • Middle Aged
  • Patient Satisfaction
  • Premenstrual Syndrome / drug therapy*
  • Premenstrual Syndrome / psychology
  • Psychiatric Status Rating Scales
  • Research Design
  • Selective Serotonin Reuptake Inhibitors / administration & dosage*
  • Treatment Outcome

Substances

  • Antidepressive Agents, Second-Generation
  • Serotonin Uptake Inhibitors
  • Citalopram